---
title: "Mayeul Ottaviani"
id: "968"
type: "collaborateur"
slug: "mayeul-ottaviani"
published_at: "2025-12-29T09:34:28+00:00"
modified_at: "2026-09-02T12:29:16+00:00"
url: "https://www.august-debouzy.com/en/collaborateur/mayeul-ottaviani/"
markdown_url: "https://www.august-debouzy.com/en/collaborateur/mayeul-ottaviani.md"
taxonomy_language:
  - "English"
taxonomy_post_translations:
  - "pll_69524b244a1b0"
taxonomy_tax_expertise:
  - "Patent Litigation"
  - "Patents"
taxonomy_tax_fonction:
  - "Associate"
taxonomy_tax_langue:
  - "English"
  - "French"
taxonomy_tax_localisation:
  - "Paris"
---

[Profil Linkedin](https://www.linkedin.com/in/mayeul-ottaviani-33335b162/)

[Voir la page Équipe](https://www.august-debouzy.com/en/team/)

# Mayeul Ottaviani

- Position Associate
- Email mottaviani@august-debouzy.com
- Phone Number +33145615981
- Languages English, French
- Location Paris
- Bar Paris Bar

## Practice Areas

- [Patent Litigation](https://www.august-debouzy.com/en/expertise/patent-litigation/)
- [Patents](https://www.august-debouzy.com/en/expertise/patents/)

0

## Biography

Admitted to the Paris Bar in 2024, Mayeul Ottaviani joined August Debouzy the same year.

Specializing primarily in patent law, he provides both advisory and litigation support to French and international clients, defending their interests before national courts and offices as well as before the Unified Patent Court (UPC). He also maintains a strong interest in FRAND issues and broader intellectual property matters.

Mayeul graduated from the University of Montpellier and gained significant experience working with leading international law firms.

## Background

- 2023 Montpellier - Université de Montpellier | Master’s degree (Master 2) - Intellectual Property and Digital Law

## *Latest* News

k

[10/09/25 Legal Article 10 min UPC Court of Appeal Clarifies Standards for Imminent Infringement in Pharmaceutical Patent Disputes The UPC Court of Appeal clarifies imminent infringement in pharma cases, overturning Boehringer v. Zentiva ruling and aligning with EU case law.](https://www.august-debouzy.com/en/legal-article/upc-court-of-appeal-clarifies-standards-for-imminent-infringement-in-pharmaceutical-patent-disputes/)

[28/05/25 Legal Article 4 min The LD Lisbon Offers Some Limited Insight on Imminent Threat of Infringement On 8 May 2025, the Lisbon Local Division of the Unified Patent Court (“UPC”) issued an order (Boehringer Ingelheim International GmbH v. Zentiva Portugal LDA, Lisbon LD, 8 May 2025, UPC_CFI_41/2025) denying a preliminary injunction application filed by Boehringer Ingelheim International GmbH (“Boehringer”) against Zentiva Portugal LDA (“Zentiva”).](https://www.august-debouzy.com/en/legal-article/the-ld-lisbon-offers-some-limited-insight-on-imminent-threat-of-infringement/)

[16/05/25 Legal Article 7 min First Unified Patent Court Ruling on Second Medical Use Claims On 13 May 2025, the Düsseldorf Local Division of the Unified Patent Court issued a landmark decision on the merits relating to a second medical use claim (Sanofi Biotechnology SAS and Regeneron Pharmaceuticals Inc. v. Amgen Inc. et al., 13 May 2025, UPC_CFI_505/2024). The decision follows an infringement action brought by Regeneron and Sanofi, respectively the proprietor and exclusive licensee of European Patent No 3 536 712 ("EP’712"), against various…](https://www.august-debouzy.com/en/legal-article/first-unified-patent-court-ruling-on-second-medical-use-claims/)

01

03

Précédent     Suivant

[Explore Our News](https://www.august-debouzy.com/en/le-hub-list/)
k

News